Previous 10 | Next 10 |
To afford a dividend, companies must make consistent profits, preferably via a business model that won't need to change significantly over time. That means they're often priced at a premium because investors love consistency, as they well should. But sometimes, a window of opportunity opens t...
Summary Bristol-Myers Squibb's revenue was $11,406 million in Q4 2022, showing mixed results compared to previous quarters, and there are many explanations for this, which will be discussed in the article. In 2023, the company's investors should receive a dividend of $2.28 per share, up...
Viatris ( NASDAQ: VTRS ) continued to trade lower pre-market Friday as BMO Capital Markets downgraded the drugmaker to Market Perform from Outperform, citing a lack of clarity on the company’s next phase of growth profile. “VTRS progressing well with strategic initiative...
Summary It’s among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie. Several drugmakers are expected to begin offering biosimilar ver...
Summary Anda's revenue generated $450 million for the company in the last three months of 2022, up $95 million from Q4 2022, driven by substantially increased demand for the company's services. Teva's European segment profit was $1,496 million in 2022, slightly up year-over-year, even t...
Viatris to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 PR Newswire PITTSBURGH , Feb. 15, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to report its fourth quarter and full year 2022 financial results on Mon...
The Nasdaq Composite is often associated with high-powered growth stocks. But there are also many quality dividend stocks in there as well, which are also focused on growth. Three stocks that could potentially give you the best of both worlds are Viatris (NASDAQ: VTRS) , Comcast ...
Summary Davis Selected Advisers 13F portfolio value increased from $14.06B to $14.71B this quarter. They increased Meta Platforms, Amazon.com, and Markel while reducing Cigna, JD.com, and Coupang. The top three positions are Berkshire Hathaway, Wells Fargo, and Capital One Financial...
The FDA has rejected a marketing application for a biosimilar version of cancer therapy bevacizumab that Viatris ( NASDAQ: VTRS ) submitted, the U.S. drugmaker's partner in India Biocon, announced. Bevacizumab is the active ingredient of Roche's ( OTCQX:RHHBY ) ( OTCQX:RHHBF )...
Summary Viatris and Organon are what can currently be described as "deep value plays" in the pharmaceutical sector. They face largely similar challenges, but on closer inspection are quite different companies. While I have already reported on Viatris' ever-changing portfolio, in this ar...
News, Short Squeeze, Breakout and More Instantly...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / No country can make every medicine people need, and no medicine is made in every country. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, w...
NORTHAMPTON, MA / ACCESSWIRE / July 18, 2024 / Viatris is a global healthcare company focused on bringing high-quality medicines to patients through a hybrid approach that bridges the traditional divide between generics and brands, combining the best of both, to more holistically address healthc...
2024-07-15 10:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...